Search Results

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

April 10, 2024

·

4 min read

Press Releases

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

November 7, 2024

·

7 min read

Drug Development

Ellipses’ next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Ellipses Pharma Limited announced the U.S. Food and Drug Administration has confirmed the company’s next generation selective RET inhibitor, EP0031/A400, is clear to progress into Phase 2 clinical development.

May 1, 2024

·

4 min read

Press Releases

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals’ EP-104IAR for the Treatment of Knee Osteoarthritis

October 15, 2024

·

9 min read

Drug Development

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX) today announced that regulators in Australia and Canada have cleared the Company’s request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).

May 23, 2024

·

10 min read

Drug Development

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX) today announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).

May 21, 2024

·

9 min read

Drug Development

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia Pharmaceuticals Inc. announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week Annual Meeting 2024.

May 14, 2024

·

6 min read

Press Releases

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

November 12, 2024

·

11 min read

Pharm Country

BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases

BioSig Technologies, Inc. announced that physicians have completed over 100 cases with the Near Field Tracking algorithm, an innovative and proprietary feature recently launched on the Company’s PURE EP™ Platform.

February 6, 2024

·

6 min read

Biotech Bay

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion.

June 21, 2024

·

3 min read